Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
Authors
Keywords
-
Journal
Acta Pharmaceutica Sinica B
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-09-26
DOI
10.1016/j.apsb.2022.09.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years
- (2022) Zhiran Ju et al. Acta Pharmaceutica Sinica B
- Natural products in drug discovery: advances and opportunities
- (2021) Atanas G. Atanasov et al. NATURE REVIEWS DRUG DISCOVERY
- Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation
- (2021) Qi Lv et al. Acta Pharmaceutica Sinica B
- Gasdermin D in pyroptosis
- (2021) Brandon Burdette et al. Acta Pharmaceutica Sinica B
- Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy
- (2021) Jinjing Wei et al. Acta Pharmaceutica Sinica B
- Costunolide Plays an Anti-Neuroinflammation Role in Lipopolysaccharide-Induced BV2 Microglial Activation by Targeting Cyclin-Dependent Kinase 2
- (2020) Yan-Chen Liu et al. MOLECULES
- Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
- (2020) R Donald Harvey et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout
- (2019) Zoltán Szekanecz et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
- (2019) Rebecca C. Coll et al. Nature Chemical Biology
- Targeting BTK in CLL: Beyond Ibrutinib
- (2019) David A. Bond et al. Current Hematologic Malignancy Reports
- Costunolide—A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential
- (2019) Dae Yong Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation
- (2019) Nathan Kelley et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current status of terpenoids as inflammasome inhibitors
- (2019) Sonsoles Hortelano et al. BIOCHEMICAL PHARMACOLOGY
- Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
- (2019) Tingting Yan et al. Acta Pharmaceutica Sinica B
- Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
- (2018) J Remon et al. ANNALS OF ONCOLOGY
- NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
- (2018) Alena Grebe et al. CIRCULATION RESEARCH
- Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
- (2018) Yi Huang et al. EMBO Molecular Medicine
- Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
- (2018) Hongbin He et al. Nature Communications
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
- (2017) Hua Jiang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Accurately extracting the signature of intermolecular interactions present in the NCI plot of the reduced density gradient versus electron density
- (2017) Corentin Lefebvre et al. PHYSICAL CHEMISTRY CHEMICAL PHYSICS
- CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation
- (2017) Tiantian Tang et al. Nature Communications
- Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
- (2016) Paul A. Jackson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
- (2016) Xing Liu et al. NATURE
- NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component
- (2015) Hexin Shi et al. NATURE IMMUNOLOGY
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
- (2015) Rebecca C Coll et al. NATURE MEDICINE
- NLRP3 inflammasome and its inhibitors: a review
- (2015) Bo-Zong Shao et al. Frontiers in Pharmacology
- Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions
- (2013) Tony K. L. Kiang et al. CLINICAL PHARMACOKINETICS
- The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
- (2011) Beckley K. Davis et al. Annual Review of Immunology
- Multiwfn: A multifunctional wavefunction analyzer
- (2011) Tian Lu et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- Two Naturally Occurring Terpenes, Dehydrocostuslactone and Costunolide, Decrease Intracellular GSH Content and Inhibit STAT3 Activation
- (2011) Elena Butturini et al. PLoS One
- Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome
- (2010) Christine Juliana et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular Mechanism of NLRP3 Inflammasome Activation
- (2010) Chengcheng Jin et al. JOURNAL OF CLINICAL IMMUNOLOGY
- A role for mitochondria in NLRP3 inflammasome activation
- (2010) Rongbin Zhou et al. NATURE
- Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes
- (2010) Seth L Masters et al. NATURE IMMUNOLOGY
- NOD-Like Receptors: Role in Innate Immunity and Inflammatory Disease
- (2008) Grace Chen et al. Annual Review of Pathology-Mechanisms of Disease
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More